17 citations
,
May 2019 in “BMJ Open” This review discusses the potential of drugs targeting the JAK/STAT pathway for dermatological diseases and outlines a protocol to assess existing evidence, reporting no new clinical results.
40 citations
,
August 2022 in “Frontiers in immunology” This review discusses the potential of JAK inhibitors as a promising treatment strategy for alopecia areata, highlighting their mechanism and recent FDA approval based on clinical trial efficacy.
11 citations
,
October 2018 in “Pediatric dermatology” In this case report, the authors describe a child with treatment-resistant alopecia areata who successfully responded to leflunomide and anthralin, proposing this combination as a potentially cost-effective alternative for managing recalcitrant cases by possibly inhibiting the JAK/STAT pathway.
June 2026 in “Frontiers in Immunology” This review highlights the potential for JAK inhibitors to effectively treat inflammatory and autoimmune skin diseases by targeting the JAK-STAT signaling pathway, advocating for an integrated approach to enhance targeted therapy.
489 citations
,
November 2021 in “Signal Transduction and Targeted Therapy” This review discusses the composition, activation, and regulation of the JAK/STAT pathway and highlights its role and inhibitors in various diseases, but reports no new experimental results.